C4X Discovery Ltd

Pentagrit is a zebrafish discovery lab offering efficacy screening services. Facilities includes state of art zebrafish facility for pre-clinical development across segments Oncology, Inflammation, Gene Therapy, Metabolic and Cardiovascular, Neurology and Infectious diseases.

Zebrafish Gene Therapy Programme
Immunogenicity Optimizer for Vector and Target DNA

Zebrafish Tumor Programme
Diffuse Intrinsic Pontine Glioma
Pancreatic Tumor
(NSCLC) Lung Cancer
Leukemia

Zebrafish Metabolic Programme
Left Ventricular Hypertrophy
Type II Diabetes
Obestity
NASH and NAFLD

Zebrafish Neuronal Programme
Parkinson’s
Alzheimer’s
Multiple Sclerosis

Zebrafish Rare Disease Programme
RETT Syndrome
Batten Disease

Zebrafish Pain Programme
Intestinal Pain
Peripheral Pain

Zebrafish Inflammation Programme
Arthritis
Psoriasis

Zebrafish Infection Programme
Dengue
Malaria
Chikungunya
Sars CoV-2

Cureline, Inc., is a global translational and biomarker CRO, focused on providing biospecimens procurement, management, and analysis services in the following areas: molecular diagnostics, biomarkers, drug R&D, preventive and predictive medicine, translational research, and personalized medicine. Since 2003, we have collaborated with leading clinical and research centers in the USA, Europe, and Asia on human tissue acquisition, processing and distribution.

We have expertise in a wide range of therapeutic fields, including Oncology, Inflammation, Cardiovascular diseases, Diabetes/Obesity, Infectious diseases (including in-hospital infections), CNS disorders, Inherited conditions, and others.

Cureline provides high-quality, well characterized human biospecimens and tissue-related services to biomedical research community allowing accelerated identification and validation of drug targets, development of companion diagnostic tests, discovery and development of biomarker assays and, overall, facilitating the personalized approach in medicine.

Our offices are located in South San Francisco (California, USA), St. Petersburg (Russia) and in Central/South-Pacific Asia. 25 employees with advanced degrees in life sciences, medicine and business development ensure implementation of the complex projects.

Founded in 2002, CELPROGEN is a biotechnology company, with over 5000 products in the market, focused on developing stem cell research and therapeutics products for regenerative medicine in cardiology, oncology, diabetes & neurology. All of Celprogen’s biological products, including stem cells, cancer stem cells, iPC’s & media with specific ECM’s, are manufactured and produced in the United States of America.

CELPROGEN provides novel molecular diagnostics and therapeutic product development solutions for Biotechnology, Pharmaceutical, In-vitro diagnostics and academic partnership for drug discovery.

It has 3 divisions:

• Therapeutic Division: Focused on Drug Discovery efforts to develop Pharmaceutical agents and Drugs in the following categories: Cardiovascular, Diabetes, Neurological, Oncology,Renal and Metabolic disorders.
• Life Science Division: Provides research tools & solutions for assays, enzymes, antibodies, antigens, stem cells, Tissue culture expansion and differentiation media, primary and established cell cultures, tumor markers, cardiac markers, proteomic and genomic reagents and assay systems for life science academic and pharmaceutical communities.
• Device Division: Provides novel ELISA based assay, protein array, DNA array and cellular based assay systems that are cost effective for Research and In-vitro diagnostics Industries.

Invivotek LLC, a member of Genesis Biotechnology Group® (GBG) is a global pre-clinical contract research organization (CRO) specializing in small animal studies for drug discovery and early optimization. Invivotek's facility was opened in 2012 and our first commercial project launched in 2013.

Invivotek offers both custom and standard pre-clinical services for drug discovery and development programs for our clients. Invivotek’s portfolio includes animal models and bioassays designed to support in vivo testing of compounds related to Immunology and Inflammation, Oncology, Metabolic, and Cardiovascular diseases. Invivotek’s in vivo testing capabilities are supported by biochemical and molecular biology techniques as well as functional assays with primary cell cultures established from various mouse tissues under disease model and normal conditions. These assays provide tools to study the mechanism of action of various test therapeutics or potential target genes and to explore drug efficacy biomarkers. The collective experience across multiple therapeutic areas in conjunction with the business and project management skills of the team working in a state-of-the-art animal facility, position Invivotek as a leading provider of preclinical in vivo services.

Jubilant Biosys Ltd (JBL) offers services in Structural Biology, Computational Chemistry, Medicinal Chemistry, in-vitro and in-vivo Biology, DMPK and Toxicology areas to various pharmaceutical and biotechnology. Jubilant Biosys Limited (JBL) is a subsidiary of Jubilant Life Sciences (a $1.3 Bn Sales Corporation) providing innovative drug discovery services to the global life sciences, agrochemicals and specialty chemicals industry through its research centers in India. Jubilant’s services in discovery research include;
Jubilant’s services in discovery research includes;
• Target Identification/Target Validation to Lead Optimization/ Preclinical candidate, for multiple therapeutic areas viz; Oncology, Metabolic Disorders, CNS, Pain, Inflammation, Fibrosis and Respiratory diseases.
• Functional services comprising of computational chemistry/ molecular modeling, medicinal chemistry, synthetic chemistry, scale-up (Non-GMP & GMP), structural biology, ADME-PK,in-vitro and in-vivo biology and IND enabling GLP toxicology.